Nivolumab Receives Accelerated Approval from FDA for Advanced Liver Cancer

The FDA has granted accelerated approval to the immunotherapy drug nivolumab (Opdivo®) for patients with advanced liver cancer who have previously been treated with the targeted therapy sorafenib (Nexavar®).

Cancer Currents: An NCI Cancer Research Blog